Terms ending in 2043
Every in-force patent on Ono Pharmaceutical Co., Ltd.'s record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,122,846 | Chimeric Antigen Receptor for Tumor Targeting In force · High confidence | Fate Therapeutics, Inc. | In force | High confidence | |
| US 12,630,510 | EP2 Antagonist In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 12,698,286 | Compound Having KDM5 Inhibitory Activity and Pharmaceutical Use Thereof In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 12,630,544 | NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF National Institutes for Quantum Science and Technology, Eisai R&D Management Co., Ltd., Ono Pharmaceutcal Co., Ltd. and Takeda Pharmaceutical Company Limited In force · High confidence | National Institutes for Quantum Science and Technology, Eisai R&D Management Co., Ltd., Ono Pharmaceutcal Co., Ltd. and Takeda Pharmaceutical Company Limited | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Ono Pharmaceutical Co., Ltd..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.